Xospata Reimbursement Marks A First For AML In England
Executive Summary
NICE has become the first reimbursement body in Europe to appraise and recommend Astellas Pharma’s drug for relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
You may also be interested in...
NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
Lilly’s Omvoh Among Nine New Drugs Securing EU Marketing Thumbs Up
A number of new drugs have taken a major step towards being approved for use in the EU after receiving the nod from the European Medicines Agency’s human medicines committee, the CHMP. Meanwhile, the marketing applications for three drugs have been withdrawn.
Bivalent COVID-19 Vaccine Bimervax Wins EU Marketing Approval
Bimervax is the first bivalent recombinant protein COVID-19 vaccine to be authorized in the EU, says Spanish company HIPRA.